EA201892385A1 - Модификация сконструированных полипептидов гемагглютинина вируса гриппа - Google Patents

Модификация сконструированных полипептидов гемагглютинина вируса гриппа

Info

Publication number
EA201892385A1
EA201892385A1 EA201892385A EA201892385A EA201892385A1 EA 201892385 A1 EA201892385 A1 EA 201892385A1 EA 201892385 A EA201892385 A EA 201892385A EA 201892385 A EA201892385 A EA 201892385A EA 201892385 A1 EA201892385 A1 EA 201892385A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hymagglutinin
modification
flu virus
polypeptides
constructed
Prior art date
Application number
EA201892385A
Other languages
English (en)
Inventor
Тод Страгнелл
Элиуд Олу
Рэймонд Оомен
Original Assignee
Санофи Пастер Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Санофи Пастер Инк. filed Critical Санофи Пастер Инк.
Publication of EA201892385A1 publication Critical patent/EA201892385A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Настоящее изобретение предусматривает, помимо прочего, модифицированные рекомбинантные полипептиды HA с расширенным профилем иммуногенности, который расширяет охват в отношении антигенно отличных штаммов вируса гриппа, а также способы их получения и применения.
EA201892385A 2016-06-03 2017-06-02 Модификация сконструированных полипептидов гемагглютинина вируса гриппа EA201892385A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662345502P 2016-06-03 2016-06-03
PCT/US2017/035738 WO2017210592A1 (en) 2016-06-03 2017-06-02 Modification of engineered influenza hemagglutinin polypeptides

Publications (1)

Publication Number Publication Date
EA201892385A1 true EA201892385A1 (ru) 2019-06-28

Family

ID=59093612

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201892385A EA201892385A1 (ru) 2016-06-03 2017-06-02 Модификация сконструированных полипептидов гемагглютинина вируса гриппа

Country Status (14)

Country Link
US (2) US11116832B2 (ru)
EP (1) EP3464327A1 (ru)
JP (3) JP7110119B2 (ru)
KR (2) KR102529010B1 (ru)
CN (2) CN115746107A (ru)
AU (2) AU2017275663B2 (ru)
BR (1) BR112018075078A2 (ru)
CA (1) CA3026094A1 (ru)
EA (1) EA201892385A1 (ru)
IL (1) IL263416A (ru)
MA (1) MA45159A (ru)
MX (2) MX2018014887A (ru)
SG (2) SG11201810758WA (ru)
WO (1) WO2017210592A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110106193B (zh) * 2019-05-23 2021-11-12 广州医科大学 一种具有低受体结合活性的高致病性h7n9禽流感病毒抗原及其制备方法
CN110106192B (zh) * 2019-05-23 2021-11-12 广州医科大学 一种具有低受体结合活性的高致病性h7n9禽流感病毒抗原及其制备方法

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
CA1283827C (en) 1986-12-18 1991-05-07 Giorgio Cirelli Appliance for injection of liquid formulations
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
ES2267100T5 (es) 1994-07-15 2011-04-08 The University Of Iowa Research Foundation Oligonucleótidos inmunomoduladores.
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
CA2281838A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
US6339068B1 (en) 1997-05-20 2002-01-15 University Of Iowa Research Foundation Vectors and methods for immunization or therapeutic protocols
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
CA2323929C (en) 1998-04-03 2004-03-09 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
WO2005018539A2 (en) 2003-06-16 2005-03-03 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
WO2006104615A2 (en) * 2005-02-24 2006-10-05 University Of Massachusetts Influenza nucleic acids, polypeptides, and uses thereof
AU2007345768B2 (en) 2006-07-27 2013-08-01 Ligocyte Pharmaceuticals, Inc. Chimeric influenza virus-like particles
US20120219584A1 (en) * 2009-10-05 2012-08-30 The United States Of America As Represented By The Secretary, Department Of Health Protection against pandemic and seasonal strains of influenza
KR101262300B1 (ko) * 2009-10-06 2013-05-20 헬릭스 주식회사 형질전환 식물 유래의 고병원성 조류독감 바이러스 단백질 백신 및 그 제조방법
AU2011302360B2 (en) 2010-09-14 2015-01-29 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Computationally optimized broadly reactive antigens for influenza
JP6169494B2 (ja) 2011-01-31 2017-07-26 ナノセラピューティクス・インコーポレイテッドＮａｎｏｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． インフルエンザａウイルスに対するヘテロサブタイプ免疫応答を誘導するための組換えウイルスベクターおよび方法
JP6113155B2 (ja) 2011-06-20 2017-04-12 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 計算で最適化した広い反応性を示すｈ１ｎ１インフルエンザの抗原
US10131695B2 (en) 2011-09-20 2018-11-20 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
WO2013044203A2 (en) 2011-09-23 2013-03-28 THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPTARTMENT OF HEALTH & HUMAN SERVICES Novel influenza hemagglutinin protein-based vaccines
US9504741B2 (en) * 2011-11-23 2016-11-29 Vacdiagn Biotechnology Co., Ltd. Immune methods against influenza viruses and combinatorial vaccines thereof
JP6336915B2 (ja) 2012-02-07 2018-06-06 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 計算で最適化した広い反応性を示すｈ３ｎ２、ｈ２ｎ２、およびｂ型インフルエンザウイルスの抗原
JP6175452B2 (ja) 2012-02-13 2017-08-02 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション ヒトおよびトリｈ５ｎ１インフルエンザのための、計算で最適化した反応性の広い抗原
CA2868330A1 (en) 2012-03-30 2013-10-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Computationally optimized broadly reactive antigens for h5n1 and h1n1 influenza viruses
SG11201503989PA (en) 2012-11-27 2015-06-29 Univ Pittsburgh Computationally optimized broadly reactive antigens for h1n1 influenza
JP2016508133A (ja) 2012-12-18 2016-03-17 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルスワクチン及びその使用
US20140286981A1 (en) 2013-03-14 2014-09-25 Wisconsin Alumni Research Foundation Broadly reactive mosaic peptide for influenza vaccine
ES2739123T3 (es) 2013-08-28 2020-01-29 Glaxosmithkline Biologicals Sa Nuevos antígenos y anticuerpos de la gripe

Also Published As

Publication number Publication date
US11116832B2 (en) 2021-09-14
JP2020141703A (ja) 2020-09-10
CA3026094A1 (en) 2017-12-07
KR20230061583A (ko) 2023-05-08
AU2017275663A1 (en) 2018-12-13
AU2022201514A1 (en) 2022-03-24
US11904012B2 (en) 2024-02-20
JP2022153591A (ja) 2022-10-12
JP7110119B2 (ja) 2022-08-01
IL263416A (en) 2019-01-31
US20220054623A1 (en) 2022-02-24
AU2017275663B2 (en) 2021-12-09
CN109563138B (zh) 2022-09-23
CN115746107A (zh) 2023-03-07
MX2018014887A (es) 2019-06-06
JP7479424B2 (ja) 2024-05-08
WO2017210592A1 (en) 2017-12-07
SG10201913650WA (en) 2020-03-30
US20200215182A1 (en) 2020-07-09
AU2022201514B2 (en) 2024-02-15
MX2023008256A (es) 2023-07-19
SG11201810758WA (en) 2018-12-28
BR112018075078A2 (pt) 2019-03-06
MA45159A (fr) 2019-04-10
CN109563138A (zh) 2019-04-02
JP2019525733A (ja) 2019-09-12
KR102529010B1 (ko) 2023-05-04
KR20190039065A (ko) 2019-04-10
EP3464327A1 (en) 2019-04-10

Similar Documents

Publication Publication Date Title
EA202091898A1 (ru) Антитела, нейтрализующие вирус иммунодефицита человека
EA201692467A1 (ru) Вакцины против вируса гриппа и их применения
EA201792500A1 (ru) Aav-опосредованная экспрессия антител против гриппа и способы их использования
EA201890527A1 (ru) Терапевтические вакцины против hpv18
PH12016501873A1 (en) Anti-influenza b virus hemagglutinin antibodies and methods of use
EA201591164A1 (ru) Вакцины против вируса гриппа и их применение
EA201791460A1 (ru) N4-гидроксицитидин и связанные с ним производные и варианты противовирусного применения
EA201490659A1 (ru) Вакцины против вируса гриппа и их применения
EA201692541A1 (ru) Вакцины против вируса гриппа и их применения
MX2021010060A (es) Produccion de virus en huevos aviares.
MX2015016755A (es) Reagrupamiento del virus de influenza.
EA201391515A1 (ru) Инактивированная вакцина вируса денге
EA201991798A1 (ru) Стабильные при хранении составы
MX2017016896A (es) Vacunas inactivadas contra la influenza canina, metodos para elaborarlas y sus usos.
EA201991377A1 (ru) Композиции универсальной вакцины против гриппа
EA201890322A1 (ru) Новый вид тобамовируса
WO2014152946A3 (en) Polypeptides for treating and/or limiting influenza infection
EA201590860A1 (ru) Варианты гемагглютинина и нейраминидазы вируса свиного гриппа
MX2018014955A (es) Vacunas atenuadas vivas del virus de la influenza equina.
EA201892385A1 (ru) Модификация сконструированных полипептидов гемагглютинина вируса гриппа
MX2019007924A (es) Vacunas contra la influenza.
WO2017053525A3 (en) Influenza vaccine and therapy
EA201791437A1 (ru) Композиции микросфер c инкапсулированным в липиде газом и соответствующие способы
EA201691203A1 (ru) Твёрдые формы тенофовира
EA201991319A1 (ru) Вакцины аттенуированного свиного гриппа и способы их изготовления и применения